Biotech · Private company

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Track this companyFree. Adds Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials22 recruiting or active

Pipeline programs3From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Pipeline3

GTAEXS617Phase 2 · Head and Neck Squamous Cell Carcinoma (HNSCC)ClinicalTrials.gov · fetched Nov 12, 2026
SoCPhase 2 · Head and Neck Squamous Cell Carcinoma (HNSCC)ClinicalTrials.gov · fetched Nov 12, 2026
EXS74539Phase 1 · Solid TumorClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials2

Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsPHASE1 · RECRUITING · started Apr 13, 2026ClinicalTrials.gov NCT07517198 · fetched Nov 12, 2026
Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsPHASE1_PHASE2 · RECRUITING · started Jul 6, 2023ClinicalTrials.gov NCT05985655 · fetched Nov 12, 2026